Volume 58, Issue 3, Pages (September 2000)

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Reduced renal function in patients with simple renal cysts

Volume 59, Issue 3, Pages (March 2001)

Volume 54, Issue 2, Pages (August 1998)

Persistent secondary hyperparathyroidism after renal transplantation

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Volume 67, Pages S1-S7 (June 2005)

Volume 55, Issue 3, Pages (March 1999)

Volume 88, Issue 5, Pages (November 2015)

The case ∣ A young woman with abdominal discomfort and a mass

Vitamin D deficiency and heart disease

Volume 67, Issue 2, Pages (February 2005)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Volume 61, Issue 4, Pages (April 2002)

Volume 63, Pages S88-S90 (June 2003)

Better nephrology for mice—and man

Kamyar Kalantar-Zadeh Kidney International

Volume 76, Pages S50-S99 (August 2009)

How to interpret the eGFR in patients with small body surface area

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 76, Issue 8, Pages (October 2009)

The need for reliable serum parathyroid hormone measurements

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Use of vitamin D in chronic kidney disease patients

Volume 56, Issue 3, Pages (September 1999)

Volume 87, Issue 2, Pages (February 2015)

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

Clinical relevance of FGF-23 in chronic kidney disease

Volume 79, Issue 1, Pages (January 2011)

The calcium–phosphorus in guidelines for CKD-MBD

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Volume 70, Issue 12, Pages (December 2006)

Persistent secondary hyperparathyroidism after renal transplantation

Volume 74, Pages S88-S93 (December 2008)

Recent experience with high-dose intravenous iron administration

Volume 68, Issue 4, Pages (October 2005)

Volume 56, Pages S31-S37 (December 1999)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 87, Issue 3, Pages (March 2015)

Reduced renal function in patients with simple renal cysts

Guillaume Jean, Bernard Charra, Charles Chazot, Guy Laurent

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

Volume 74, Issue 5, Pages (September 2008)

Volume 57, Issue 4, Pages (April 2000)

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 55, Issue 5, Pages (May 1999)

Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients B. Bammens, P. Evenepoel, H. Keuleers,

Volume 56, Issue 4, Pages (October 1999)

Volume 54, Issue 1, Pages (July 1998)

Volume 56, Issue 3, Pages (September 1999)

Latest findings in phosphate homeostasis

Volume 63, Pages S79-S82 (June 2003)

The course of the remnant kidney model in mice

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Recent developments in the management of secondary hyperparathyroidism

Volume 70, Issue 5, Pages (September 2006)

Volume 62, Issue 5, (November 2002)

Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease Aquiles Jara, Arnold J. Felsenfeld, Jordi.

Strategies for iron supplementation: Oral versus intravenous

Volume 67, Issue 5, Pages (May 2005)

Rebound kinetics of β2-microglobulin after hemodialysis

Taqumpay Esmiraldo Tigcal Sacamay, W. Kline Bolton

Volume 61, Issue 4, Pages (April 2002)

Peter Stenvinkel, Olof Heimbürger, Catherine H. Tuck, Lars Berglund

Volume 56, Issue 6, Pages (December 1999)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 58, Issue 3, Pages 981-988 (September 2000) No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism Gianluigi Ardissino, Claus Peter Schmitt, Maria Luisa Bianchi, Valeria Daccò, Aldo Claris-Appiani, Otto Mehls Kidney International Volume 58, Issue 3, Pages 981-988 (September 2000) DOI: 10.1046/j.1523-1755.2000.00255.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Study design (Sr test, strontium absorption test). Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Time course of 1,25(OH)2D3 serum concentration following a calcitriol bolus (1.5 μg/m2) given orally (▪) or intravenously (•). For intravenous calcitriol, an additional determination was performed five minutes after calcitriol injection (mean ± SEM, *P < 0.01). Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Box plot of the percentage decrease from baseline of intact parathyroid hormone (iPTH) after a bolus of calcitriol (1.5 μg/m2) given orally (□) and intravenously ().*P < 0.05. Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Box plot of the percentage decrease from baseline of intact parathyroid hormone (iPTH) after a bolus of calcitriol (1.5 μg/m2) given orally (□) and intravenously ().*P < 0.05. Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Time course of Sr fractional absorption without calcitriol (▴) and 24 hours after a calcitriol bolus (1.5 μg/m2) given orally (▪) and intravenously (○) in children with secondary hyperparathyroidism (mean ± SEM). Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Individual SrAUC0–240min following the administration of an oral and an IV calcitriol bolus. Symbols indicate the patient's order of calcitriol administration: oral followed by intravenous (□); intravenous followed by oral (○). Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 6 Relationship between creatinine clearance (CCr) and Sr intestinal absorption measured 24 hours after an oral (A) and an intravenous (B) calcitriol bolus. SrAUC0–240min is the area under the Sr fractional absorption time curve. Kidney International 2000 58, 981-988DOI: (10.1046/j.1523-1755.2000.00255.x) Copyright © 2000 International Society of Nephrology Terms and Conditions